Consumers Criticize $354M BARDA Award To Phlow Over Price Concerns

By John Wilkerson / May 20, 2020 at 4:45 PM
Consumer lobbyists are skeptical of HHS’ $354 million award to Virginia start-up Phlow Corp. to make generic drugs for hospitals because one of the company’s founders was an executive at a company that quintupled the price of naloxone during the opioid epidemic. HHS’ Biomedical Advanced Research and Development Authority granted the award, which can be extended to $812 million. Phlow will use the money to produce drugs that treat hospitalized patients for COVID-19-related illnesses. The company also will stockpile ingredients...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.